Gentherm Incorporated designs, develops, manufactures and markets thermal management technologies. The company is headquartered in Northville, Michigan.
| Revenue (TTM) | $1.54B |
| Gross Profit (TTM) | $372.94M |
| EBITDA | $167.65M |
| Operating Margin | 8.33% |
| Return on Equity | 3.32% |
| Return on Assets | 5.09% |
| Revenue/Share (TTM) | $50.41 |
| Book Value | $23.36 |
| Price-to-Book | 1.45 |
| Price-to-Sales (TTM) | 0.69 |
| EV/Revenue | 0.738 |
| EV/EBITDA | 10.42 |
| Quarterly Earnings Growth (YoY) | -81.20% |
| Quarterly Revenue Growth (YoY) | 11.30% |
| Shares Outstanding | $30.67M |
| Float | $30.11M |
| % Insiders | 1.84% |
| % Institutions | 103.54% |
Volatility is currently contracting
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
NOVI, Mich., July 07, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), a global market leader of innovative thermal management and pneumatic comfort technologies, will report its financial results for the second quarter 2026 on Thursday, July 23, 2026, and will host a conference call to discuss those results at 8 am (ET) that same day.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Company Announces Shares for Debt Settlements Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous shipments, Horizon Health USA has placed a new order for 100 Venowave units.
Gentherm Incorporated remains a soft Buy as its transformation and merger with Modine Performance Technologies drive significant upside potential. THRM delivered impressive Q1 FY2026 results: sales up 11.2% to $393.7M, outpacing a contracting vehicle production market. Management guides for FY2026 revenue of $1.5–$1.6B and EBITDA of $175–$195M, with the Modine merger expected to boost combined revenue to $2.6B and EBITDA to $322M.
The market consistently misprices the physical infrastructure required to sustain exponential technological growth. Right now, the structural bottleneck for artificial intelligence (AI) is not silicon availability.
NOVI, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM) a global market leader of innovative thermal management and pneumatic comfort technologies, has been presented with a 2025 Supplier of the Year Award at General Motors' 34th annual Supplier of the Year event in Austin, Texas.
NOVI, Mich., May 20, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), a global market leader of innovative thermal management and pneumatic comfort technologies, today announced that it is scheduled to participate in the following upcoming investor conference in the second quarter of 2026.
NOVI, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), a global market leader of innovative thermal management and pneumatic comfort technologies, today announced it will showcase its latest expansion into the Home and Office market at NeoCon 2026 in Chicago, IL including Preview Day on June 7, 2026 and exhibit days June 8–10, 2026.
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
